Al-Sabbagh A - Search Results

1

Patient satisfaction with an injection device for multiple sclerosis treatment.

Cramer JA, Cuffel BJ, Divan V, Al-Sabbagh A, Glassman M. Cramer JA, et al. Acta Neurol Scand. 2006 Mar;113(3):156-62. doi: 10.1111/j.1600-0404.2005.00568.x. Acta Neurol Scand. 2006. PMID: 16441244 Clinical Trial.

2

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.

Freedman MS, Hughes B, Mikol DD, Bennett R, Cuffel B, Divan V, LaVallee N, Al-Sabbagh A. Freedman MS, et al. Eur Neurol. 2008;60(1):1-11. doi: 10.1159/000127972. Epub 2008 Apr 25. Eur Neurol. 2008. PMID: 18437041 Free article. Review.

3

Response to interferon beta-1a treatment in African American multiple sclerosis patients.

Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Cree BA, et al. Arch Neurol. 2005 Nov;62(11):1681-3. doi: 10.1001/archneur.62.11.1681. Arch Neurol. 2005. PMID: 16286540

4

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Goldberg LD, et al. J Manag Care Pharm. 2009 Sep;15(7):543-55. doi: 10.18553/jmcp.2009.15.7.543. J Manag Care Pharm. 2009. PMID: 19739877 Free PMC article.

5

Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.

Traboulsee A, Al-Sabbagh A, Bennett R, Chang P, Li DK; EVIDENCE Study Group; UBC MS/MRI Research Group. Traboulsee A, et al. BMC Neurol. 2008 Apr 21;8:11. doi: 10.1186/1471-2377-8-11. BMC Neurol. 2008. PMID: 18426595 Free PMC article. Clinical Trial.

6

Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Guo S, Bozkaya D, Ward A, O'Brien JA, Ishak K, Bennett R, Al-Sabbagh A, Meletiche DM. Guo S, et al. Pharmacoeconomics. 2009;27(1):39-53. doi: 10.2165/00019053-200927010-00005. Pharmacoeconomics. 2009. PMID: 19178123

7

Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study.

Funch D, Norman H, Wong J, Bennett R, Hillier J, Al-Sabbagh A, Seeger JD. Funch D, et al. Pharmacoepidemiol Drug Saf. 2010 May;19(5):448-56. doi: 10.1002/pds.1918. Pharmacoepidemiol Drug Saf. 2010. PMID: 20333778

8

Effect of oral beta interferon on subsequent immune responsiveness.

Nelson PA, Akselband Y, Dearborn SM, Al-Sabbagh A, Tian ZJ, Gonnella PA, Zamvil SS, Chen Y, Weiner HL. Nelson PA, et al. Ann N Y Acad Sci. 1996 Feb 13;778:145-55. doi: 10.1111/j.1749-6632.1996.tb21123.x. Ann N Y Acad Sci. 1996. PMID: 8610968

9

The role of optical coherence tomography in multiple sclerosis: expert panel consensus.

Sergott RC, Frohman E, Glanzman R, Al-Sabbagh A; OCT in MS Expert Panel. Sergott RC, et al. J Neurol Sci. 2007 Dec 15;263(1-2):3-14. doi: 10.1016/j.jns.2007.05.024. Epub 2007 Jul 27. J Neurol Sci. 2007. PMID: 17673257 Review.

10

Decreased CNS inflammation and absence of clinical exacerbation of disease after six months oral administration of bovine myelin in diseased SJL/J mice with chronic relapsing experimental autoimmune encephalomyelitis.

al-Sabbagh AM, Goad EP, Weiner HL, Nelson PA. al-Sabbagh AM, et al. J Neurosci Res. 1996 Aug 15;45(4):424-9. doi: 10.1002/(SICI)1097-4547(19960815)45:4<424::AID-JNR11>3.0.CO;2-0. J Neurosci Res. 1996. PMID: 8872902

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

80 results

Search Page